Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07422012 · ClinicalTrials.gov registry record
Tacrolimus in Pregnancy
A clinical trial, sponsored by Baylor Research Institute.
- Not yet
- Registry status
- 55
- Enrollment target
NCT07422012: Clinical Trial study, sponsored by Baylor Research Institute.
NCT07422012 is a clinical trial that has not yet begun recruiting, run by Baylor Research Institute. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07422012 has not yet begun recruiting, sponsored by Baylor Research Institute.
- NOT YET RECRUITING
- Registry status
- 55 participants
- Enrollment target
Study Summary
To create a formula that adjusts tacrolimus blood levels. This is needed because pregnant patients have higher levels of unbound tacrolimus. The adjusted formula will give a more accurate measure of the active drug in pregnant uterus transplant patients.
Primary Outcome
Develop a joint non-linear mixed effect population pharmacokinetic model describing bound and unbound tacrolimus pharmacokinetics in pregnant subjects.
Interventions
- BIOLOGICAL Modeling of unbound and whole blood tacrolimus in pregnant uterus transplant recipients
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2026-05-31 |
| Est. Completion | 2028-03 |
What is known before NCT07422012 opens enrollment
NCT07422012 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Modeling of unbound and whole blood tacrolimus in pregnant uterus transplant recipients is the first listed.
NCT07422012 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07422012 about?
NCT07422012 is a clinical study titled "Tacrolimus in Pregnancy". To create a formula that adjusts tacrolimus blood levels. This is needed because pregnant patients have higher levels of unbound tacrolimus. The adjusted formula will give a more accurate measure of the active drug in pregnant uterus transplant patients.
What is the current status of trial NCT07422012?
This trial is currently not yet recruiting. The enrollment target is 55 participants. The study started on 2026-05-31. Estimated completion is 2028-03.
What interventions are being tested in trial NCT07422012?
The interventions under investigation include: Modeling of unbound and whole blood tacrolimus in pregnant uterus transplant recipients (BIOLOGICAL).
Who is sponsoring clinical trial NCT07422012?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI